

References

I-247

1. Vyvgart® (efgartigmod alfa-fcab), injection for intravenous use [package insert]. Argenx. Boston, MA. Revised 01/2024.
2. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Efgartigmod alfa-fcab.
3. Micromedex DrugDex Compendium®. 2024. Efgartigmod alfa-fcab.
4. Efgartigmod alfa-fcab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated May 10, 2024.
5. Howard JF, Bril V, Burns TM et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. *Neurology*. 2019;92:2661-73.
6. Howard JF, Bril V, Vu T et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicentre, randomized, placebo-controlled, phase 3 trial. *Lancet Neurol*. 2021;20(7):526-36.
7. Vyvgart® Hytrulo (efgartigmod alfa and hyaluronidase-qvfc), injection for subcutaneous use [package insert]. Argenx. Boston, MA. Revised 06/2024.
8. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Efgartigmod alfa and hyaluronidase-qvfc.
9. Micromedex DrugDex Compendium®. 2024. Efgartigmod alfa and hyaluronidase-qvfc.
10. Bird SJ. Overview of the treatment of myasthenia gravis. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on July 8, 2024).
11. Narayanaswami P, Sanders D, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis. *Neurology*. 2021;96:114-122.
12. Van den Bergh P, van Doorn P, Hadden R, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. *J Peripher Nerv Syst*. 2021;28(11):3556-3583.